Regeneron Pharmaceuticals Profile

USD 0.07  0.0222%

Purchase by Sanofi of 1871 shares of Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc insider trading alert for perchase of common stock by Sanofi, the corporate stakeholder, on February 15, 2018. This event was filed by Regeneron Pharmaceuticals with SEC on 2014-09-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Regeneron Pharmaceuticals Summary

Regeneron Pharmaceuticals Inc (REGN) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 6,200 people. Regeneron Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 35.71 B. Regeneron Pharmaceuticals Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 105.61 M outstanding shares of which 2.13 M shares are at this time shorted by private and institutional investors with about 2.32 trading days to cover. REGENERON PHARMAC currently holds about 1.41 B in cash with 1.31 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.11.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Regeneron Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Regeneron Pharmaceuticals Against Markets

Current Ratings

Regeneron Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 1% 
Equity ratings for Regeneron Pharmaceuticals Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 6200 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameRegeneron Pharmaceuticals Inc
President CEO, DirectorLeonard SchleiferAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationNEW YORK, U.S.A
Business Address777 Old Saw Mill River Road
Foreign Associates
CIK Number00872589.0
Contact Number914 847 7000
CurrencyUSD - US Dollar


Regeneron Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
Regeneron Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Regeneron Pharmaceuticals Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Regeneron Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate2.5May 4, 2017
Regeneron Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Regeneron Pharmaceuticals Corporate Directors
Charles Baker Independent Director
Joseph Goldstein Independent Director, Ph.D
Anthony Coles Independent Director